http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Claus F. Vogelmeier ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Goals of COPD Treatment: Focus on Symptoms and Exacerbations
( Claus F. Vogelmeier ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
The two clinical parameters that guide treatment in COPD patients are “symptoms” and “exacerbations”. In patients with symptoms only ㆍ many patients on mono-bronchodilator treatment are still symptomatic ㆍEMAX was the first major prospective study testing the efficacy of LAMA/LABA versus monotherapies in patients without ICS. EMAX showed consistent and sustained benefit of LAMA/LABA over monotherapies In patients with symptoms + exacerbations ㆍ + blood eosinophils >100/μl escalation to LAMA/LABA/ICS may improve symptoms, reduce exacerbations and mortality
-
Should You Initiate Treatment with One or Two Bronchodilators?
( Claus F. Vogelmeier ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Guideline documents give conflicting recommendations how to initiate treatment in a newly diagnosed symtomatic COPD patient with no major exacerbation history: some recommend to start with a single long-acting bronchodilator (LAMA), some to start with a LAMA/LABA combination. There is evidence that many patients on mono-bronchodilator treatment are (still) highly symptomatic. Most studies that evaluated the efficacy of dual bronchodilators have been compromised by the concurrent use of ICS in a considerable part of the included patient population. The EMAX study is the first major prospective study testing the efficacy of LAMA/LABA versus monotherapies in patients without ICS. EMAX showed a consistent and sustained benefit of LAMA/ LABA (umeclidinium/vilanterol) over monotherapies including clinically important improvements in lung function versus monotherapies in both maintenance treated and maintenance naive subgroups. If patients do not improve with dual bronchodilator treatment, non-pharmacologic treatments and comorbidities have to be considered.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
